Pfizer Inc
PFE23.870USD
-0.980-3.94%
종가 09/12, 16:00（ET）시세는 15분 지연됩니다
135.70B시가총액
12.62P/E TTM
자세한 내용은 Pfizer Inc 회사
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.
회사 정보
종목 코드 PFE
회사 이름Pfizer Inc
상장일Jan 17, 1944
CEODr. Albert Bourla, Ph.D.
직원 수81000
유형Ordinary Share
회계 연도 종료Jan 17
주소66 Hudson Boulevard East
도시NEW YORK
증권 거래소NYSE Consolidated
국가United States of America
우편 번호10001-2192
전화12127332323
웹사이트https://www.pfizer.com/
종목 코드 PFE
상장일Jan 17, 1944
CEODr. Albert Bourla, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
Mr. Aamir Malik
Mr. Aamir Malik
Executive Vice President, Chief US Commercial Officer
Executive Vice President, Chief US Commercial Officer
29.55K
+7800.53%
Ms. Payal Sahni
Ms. Payal Sahni
Executive Vice President, Chief People Experience Officer
Executive Vice President, Chief People Experience Officer
24.85K
+6.62%
Mr. Cyrus Taraporevala
Mr. Cyrus Taraporevala
Independent Director
Independent Director
10.00K
--
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
10.00K
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
수익 분석
통화: USD마지막 업데이트: Sun, Jul 6
통화: USD마지막 업데이트: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
사업별USD
이름
수익
비율
Eliquis alliance revenues and direct sales
1.92B
14.02%
Prevnar family
1.66B
12.10%
Vyndaqel family
1.49B
10.83%
All other Hospital
1.16B
8.42%
Oncology-Ibrance
977.00M
7.12%
기타
6.51B
47.50%
지역별USD
이름
수익
비율
United States
8.37B
61.06%
Developed Markets
3.18B
23.17%
Emerging Markets
2.16B
15.77%
사업별
지역별
사업별USD
이름
수익
비율
Eliquis alliance revenues and direct sales
1.92B
14.02%
Prevnar family
1.66B
12.10%
Vyndaqel family
1.49B
10.83%
All other Hospital
1.16B
8.42%
Oncology-Ibrance
977.00M
7.12%
기타
6.51B
47.50%
주식 보유 통계
마지막 업데이트: Fri, Aug 15
마지막 업데이트: Fri, Aug 15
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
9.33%
State Street Global Advisors (US)
5.21%
BlackRock Institutional Trust Company, N.A.
5.08%
Geode Capital Management, L.L.C.
2.24%
Norges Bank Investment Management (NBIM)
1.65%
기타
76.48%
주주
주주
비율
The Vanguard Group, Inc.
9.33%
State Street Global Advisors (US)
5.21%
BlackRock Institutional Trust Company, N.A.
5.08%
Geode Capital Management, L.L.C.
2.24%
Norges Bank Investment Management (NBIM)
1.65%
기타
76.48%
주주 유형
주주
비율
Investment Advisor
32.84%
Investment Advisor/Hedge Fund
22.84%
Research Firm
3.11%
Pension Fund
2.26%
Bank and Trust
1.84%
Sovereign Wealth Fund
1.76%
Hedge Fund
1.27%
Insurance Company
1.24%
Holding Company
0.05%
기타
32.80%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
4945
3.85B
67.75%
-89.09M
2025Q1
5074
3.86B
67.90%
-51.97M
2024Q4
5153
3.84B
67.74%
-83.26M
2024Q3
5005
3.85B
67.99%
-51.77M
2024Q2
5026
3.84B
67.75%
-120.77M
2024Q1
5032
3.89B
68.71%
-120.39M
2023Q4
5089
3.97B
70.25%
-96.67M
2023Q3
4952
4.00B
70.89%
-71.80M
2023Q2
4962
4.02B
71.16%
-62.35M
2023Q1
4947
4.02B
71.28%
-30.98M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
520.58M
9.16%
+4.61M
+0.89%
Mar 31, 2025
State Street Global Advisors (US)
296.97M
5.22%
+6.49M
+2.23%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
291.55M
5.13%
+12.00M
+4.29%
Mar 31, 2025
Geode Capital Management, L.L.C.
125.65M
2.21%
+5.06M
+4.20%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
87.79M
1.54%
+3.82M
+4.55%
Dec 31, 2024
Wellington Management Company, LLP
103.49M
1.82%
-36.50M
-26.07%
Mar 31, 2025
MFS Investment Management
73.03M
1.28%
-1.19M
-1.60%
Mar 31, 2025
State Farm Insurance Companies
57.75M
1.02%
+493.70K
+0.86%
Mar 31, 2025
BlackRock Asset Management Ireland Limited
50.47M
0.89%
+4.52M
+9.83%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
48.03M
0.84%
-107.43M
-69.10%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Tue, Sep 2
마지막 업데이트: Tue, Sep 2
이름
비율
Franklin US Dividend Booster Index ETF
128.98%
First Trust NASDAQ Pharmaceuticals ETF
7.17%
First Trust Morningstar Dividend Leaders Index Fund
6.24%
Amplify Weight Loss Drug & Treatment ETF
5.07%
Coastal Compass 100 ETF
4.82%
Invesco Pharmaceuticals ETF
4.82%
WBI Power Factor High Dividend ETF
4.75%
LSV Disciplined Value ETF
4.68%
Vaneck Durable High Dividend ETF
4.38%
iShares U.S. Pharmaceuticals ETF
4.28%
더 보기
Franklin US Dividend Booster Index ETF
비율128.98%
First Trust NASDAQ Pharmaceuticals ETF
비율7.17%
First Trust Morningstar Dividend Leaders Index Fund
비율6.24%
Amplify Weight Loss Drug & Treatment ETF
비율5.07%
Coastal Compass 100 ETF
비율4.82%
Invesco Pharmaceuticals ETF
비율4.82%
WBI Power Factor High Dividend ETF
비율4.75%
LSV Disciplined Value ETF
비율4.68%
Vaneck Durable High Dividend ETF
비율4.38%
iShares U.S. Pharmaceuticals ETF
비율4.28%
주식 배당금
지난 5년 동안 총
44.91B
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
Dec 12, 2024
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025
Jan 24, 2025
Mar 07, 2025
Jan 24, 2025
Oct 09, 2024
PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024
Nov 08, 2024
Dec 02, 2024
Nov 08, 2024
Jun 26, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024
Jul 26, 2024
Sep 03, 2024
Jul 26, 2024
Apr 24, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024
May 10, 2024
Jun 14, 2024
May 09, 2024
Dec 14, 2023
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024
Jan 26, 2024
Mar 01, 2024
Jan 25, 2024
Oct 04, 2023
PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Dec 04, 2023
Nov 09, 2023
Jun 22, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Sep 05, 2023 going ex on Jul 27, 2023
Jul 28, 2023
Sep 05, 2023
Jul 27, 2023
Apr 26, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Jun 09, 2023 going ex on May 11, 2023
May 12, 2023
Jun 09, 2023
May 11, 2023
Dec 09, 2022
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Mar 03, 2023 going ex on Jan 26, 2023
Jan 27, 2023
Mar 03, 2023
Jan 26, 2023
Sep 22, 2022
PFE.NB Final Cash Dividend of gross USD 0.4 paid on Dec 05, 2022 going ex on Nov 03, 2022
Nov 04, 2022
Dec 05, 2022
Nov 03, 2022
더 보기
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
